About MRC-Holland
MRC-Holland b.v. is a biotechnology company located in Amsterdam, the Netherlands. The company is a follow-up of Microbiology Research Centre Holland, founded in 1985 by Dr. Jan Schouten. Until 2000, the main products of MRC-Holland were restriction endonucleases—purified from a wide range of bacteria and blue green algae—and DNA molecular weight markers. These products were sold in bulk amounts to distributing companies worldwide.

In 1997, MRC-Holland started focusing on developing new techniques for DNA analysis. By far the most successful technique developed is Multiplex Ligation-dependent Probe Amplification, or MLPA®. The MLPA® technology was first described in Nucleic Acids Research 30, e57 (2002) by Schouten et al. Since then, hundreds of MLPA probe sets have been developed for a wide variety of genes and applications, some of which very rare.

At present, most activities of MRC-Holland are directed to the production of new MLPA-based products and the development of novel MLPA-based techniques. MRC-Holland currently has more than 80 employees, working in development, quality testing, production, sales and customer service.

Quality Management
Quality is very important to MRC-Holland. We have obtained an ISO 13485 certification for our Quality Management System. Compliance with the standard was assessed by Lloyd's Register Quality Assurance Limited (LRQA). The certificate can be downloaded here.


One of MRC-Holland's buildings.
Improved Products
P090-BRCA2
Breast and ovarian cancer, hereditary (HBOC)
P239-BRCA1 region
Breast cancer
P188-22q13
Phelan-Mcdermid syndrome
P045-BRCA2/CHEK2
Breast and ovarian cancer, hereditary (HBOC); Susceptibility to breast cancer; Susceptibility to other cancer types
P315-EGFR
Tumours, solid
Newsletter  |  Home  |  Privacy Policy  |  Terms and Conditions  |  Search  |  Sitemap  |  Copyright © 2019 MRC-Holland